메뉴 건너뛰기
Leukemia and Lymphoma
Volumn 50, Issue 11, 2009, Pages 1889-1891
The effect of homoharringtonine in patients with chronic myeloid leukemia who have failed or responded suboptimally to imatinib therapy
Author keywords

[No Author keywords available]
Indexed keywords

HOMOHARRINGTONINE; IMATINIB;
EID: 71049133485     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428190903216838     Document Type: Letter
Times cited : (14)
References (7)
  • 1
    • 9144234689 scopus 로고    scopus 로고
    • Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia
    • Donato NJ,Wu JY, Stapley J, et al. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res 2004;64:672-677.
    • (2004) Cancer Res , vol.64 , pp. 672-677
    • Donato Njwu, J.Y.1    Stapley, J.2
  • 2
    • 65249185560 scopus 로고    scopus 로고
    • Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia
    • Quintás-Cardama A, Kantarjian HM, Cortes JE. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control 2009;16: 122-131.
    • (2009) Cancer Control , vol.16 , pp. 122-131
    • Quintás-Cardama, A.1    Kantarjian, H.M.2    Cortes, J.E.3
  • 3
    • 17644395643 scopus 로고    scopus 로고
    • Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib
    • Marin D, Kaeda JS, Andreasson C, et al. Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib. Cancer 2005;103:1850-1855.
    • (2005) Cancer , vol.103 , pp. 1850-1855
    • Marin, D.1    Kaeda, J.S.2    Andreasson, C.3
  • 4
    • 33846261532 scopus 로고    scopus 로고
    • Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy
    • Quintás-Cardama A, Kantarjian H, Garcia-Manero G, et al. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 2007;109:248-255.
    • (2007) Cancer , vol.109 , pp. 248-255
    • Quintás-Cardama, A.1    Kantarjian, H.2    Garcia-Manero, G.3
  • 5
    • 33845285906 scopus 로고    scopus 로고
    • A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia
    • Chen R, Gandhi V, Plunkett W. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res 2006;66:10959-10966.
    • (2006) Cancer Res , vol.66 , pp. 10959-10966
    • Chen, R.1    Gandhi, V.2    Plunkett, W.3
  • 6
    • 33747154547 scopus 로고    scopus 로고
    • Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet
    • Baccarani M, Saglio G, Goldman J. Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809-1820.
    • (2006) Blood , vol.108 , pp. 1809-1820
    • Baccarani, M.1    Saglio, G.2    Goldman, J.3
  • 7
    • 41449106741 scopus 로고    scopus 로고
    • Monitoring treatment of chronic myeloid leukemia
    • Baccarani M, Pane F, Saglio G. Monitoring treatment of chronic myeloid leukemia. Haematologica 2008;93:161-169.
    • (2008) Haematologica , vol.93 , pp. 161-169
    • Baccarani, M.1    Pane, F.2    Saglio, G.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.